PMX 205
NRP1 antagonist 1
Zilucoplan
Ravulizumab
Lampalizumab
Vesencumab
Tesidolumab
Vilobelimab
Avdoralimab
Pexelizumab
Gavilimomab
Gefurulimab
Pozelimab
Olendalizumab
Crovalimab
Riliprubart
Empasiprubart
Zoracopan
BCX 1470
Sutimlimab